Chemoradiotherapy for colorectal cancer

Gut

Volumn 54, Issue 8, 2005, Pages 1194-1202

  Andre, N ^a   Schmiegel, W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EDRECOLOMAB; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; LOPERAMIDE; OXALIPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; UFT;

ACNE; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DIARRHEA; DRUG RECEPTOR BINDING; DYSESTHESIA; HUMAN; HYPERTENSION; LIVER METASTASIS; NAUSEA; NEUROLOGIC DISEASE; PARESTHESIA; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SENSORY NEUROPATHY; STOMACH PERFORATION;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; PALLIATIVE CARE; PYRIMIDINES; RECTAL NEOPLASMS;

EID: 22644440007     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.062745     Document Type: Review

References (81)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8.
2. Russo MW, Wei JT, Thiny MT, et al. Digestive and liver diseases statistics, 2004. Gastroenterology 2004;126:1448-53.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
4. Abulafi AM. Williams NSLocal recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 1994;81:7-19.
5. Faivre-Finn C, Bouvier AM, Mitry E, et al. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? Aliment Pharmacol Ther 2002;16:353-9.
6. Colorectal Cancer. In: Steward BW, Kleihues P, eds. World Cancer Report. Lyon: IARC Press, 2003:198-202.
7. Berrino F, Gatta G, Chessa E, et al. The EUROCARE II study. Eur J Cancer 1998;34:2139-53.
8. Gatta G, Faivre J, Capocaccia R, et al. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 1998;34:2176-83.
9. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-806.
10. Seymour MT, Stenning SP, Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol 1997;9:248-51.
11. Dukes CE. The classification of cancer of the rectum. J Pathol 1932;35:323-32.
12. Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846-52.
13. Sobin LH, Wittekind C. UICC: TNM classifcation of malignant tumours, 6th edn. London: John Wiley & Sons, 2002.
14. Greene FL, Balch CM, Fleming ID, et al. eds. AJCC cancer staging handbook, 6th edn. New York: Springer, 2002.
15. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
16. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
17. Haller DG, Lefkopoulou M, Macdonald JS, et al. Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089). AoV Exp Med Biol 1993;339:51-6.
18. Haller DG, Catalano PJ, Macdonald JS, et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol 1998;17:982.
19. Benson AB, Schrag D, Somereld MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19.
20. Figueredo A, Charette M, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004;22:3395-407.
21. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-7.
22. Martenson JA, Willett CG, Sargent DJ, et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol 2004;22:3277-83.
23. Punt G, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002;360:671-7.
24. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-9.
25. Porschen R, Bermann A, Loffler T, et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001;19:1787-94.
26. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol 2004;22(suppl):3500.
27. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
28. deGramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. Proceedings of the 2005 Gastrointestinal Cancers Symposium, San Francisco, USA, January 22-24, 2005:167.
29. Colacchio TA, Niedzwiecki D, Compton C, et al. Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). J Clin Oncol 2004;22:3522.
30. Gray RG, Barnwell J, Hills R, et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. J Clin Oncol 2004;22:3501.
31. Heald RJ, Moran BJ, Ryall RD, et al. MacFarlane JKRectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998;133:894-9.
32. Kapiteijn E, Marijnen CAM, Nagetgaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
33. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
34. Gunderson LL, Haddock MG, Schild SE. Rectal cancer: preoperative versus postoperative irradiation as a component of adjuvant treatment. Semin Radiat Oncol 2003;13:419-32.
35. van den Brink M, van den Hout W, Stiggelbout AM, et al. Cost utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: the dutch colorectal cancer group. J Clin Oncol 2004;22:244-53.
36. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
37. Bosset JF, Calais G, Daban A, et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC radiotherapy group. Eur J Cancer 2004;40:219-24.
38. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-5.
39. Kohne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721-8.
40. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 1998;42(suppl):S31-43.
41. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-18.
42. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998 Oct 31;352:1407-12
43. (erratum appears in Lancet 1998;352:1634).
44. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
45. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7
46. (erratum appears in Lancet 2000;355:1372).
47. Raymond E, Buquet-Fagot C, Djelloul S, et al. Antitumour activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:876-85.
48. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
49. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998;16:2739-44.
50. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105-8.
51. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
52. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
53. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). American Society of Clinical Oncology 38th Annual Meeting, Orlando, Florida, May 18-21, 2002.
54. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
55. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
56. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Prog Proc Am Soc Clin Oncol 2003;22:255.
57. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.
58. Pazdur R, Douiliard JY, Skillings JR, et al. Multicenter phase III study of 5-fluoruracil (5-FU) or UFTTM in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Oncol 1999;18:263a.
59. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of ORZEL (oral uracil/Tegafur) (UFTTM) plus leucovorin (LV) versus parenteral 5-fluoruracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:264a.
60. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluoruracil plus leucovorin as first line therapy in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
61. Van Cutsem E, Twelfes C, Cassidy J, et al. Oral capecitabine compared with intravenous fluoruracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097-106.
62. Arkenau H, Kubicka S, Greil R, et al. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma: Results of an interim efficacy and safety analysis. ASCO 2005 Gastrointestinal Cancers Symposium, San Francisco, USA, 22-24 January 2005: abstract 226.
63. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
64. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastasis from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-20.
65. Giachetti B, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluoruracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-9.
66. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7(suppl 4):2-8.
67. Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am 2002;16:1041-13.
68. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Prog Proc Am Soc Clin Oncol 2001;20:3a.
69. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
70. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Prog Proc Am Soc Clin Oncol 2003;22:204a.
71. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-8.
72. Saltz LB, Lenz H, Kindler H, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. ASCO 2005 Gastrointestinal Cancers Symposium, San Francisco, USA, 22-24 January 2005: abstract 169b.
73. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
74. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
75. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
76. Kabbinavar F, Schulz J, McCleod M, et al. Bevacizumab (Avastin), a monoclonal antibody to vascular endothelial growth factor, prolongs progression-free survival in first-line colorectal cancer in subjects who are not suitable candidates for first-line CPT-11. J Clin Oncol 2004;22(suppl):3516.
77. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Group (ECOG) study E2300. Proceedings of the 2005 Gastrointestinal Cancers Symposium, San Francisco, USA, 22-24 January, 2005:168.
78. Goss GD, Stewart DJ, Hirte H, et al. Initial results of part 2 of a phase I/II pharmacokinetic, pharmacodynamic and biological activity study of ZD 1839. Proc Am Soc Clin Oncol 2002;21:16a.
79. Oza AM, Townsley CA, Siu LL, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:196a.
80. Cho CD, Fisher GA, Halsey J, et al. A phase II study of Geftinib in combination with FOLFOX4 in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:265a.
81. Messersmith WA, Laheru DA, Senzer NN, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004;10:6522-7.